Daniel M. Geynisman, MD, on a Strategic Approach to Neoadjuvant Treatment of Bladder Cancer

Posted: Monday, February 22, 2021

Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses the strategy used in the RETAIN BLADDER study, in conjunction with neoadjuvant chemotherapy, to reduce the extent of eventual surgical intervention for patients with bladder cancer.